Midora

Amisulpride, the active ingredient in Midora, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the treatment of schizophrenia, other psychotic disorders, and as an adjunct in major depressive disorder in adult patients.

GNH USA supplies Midora as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory support for cross‑border distribution. Midora is manufactured under strict GMP conditions and is available in multiple batch releases to meet global demand.

Amisulpride is used to manage conditions within the schizophrenia spectrum and related psychotic disorders. - Schizophrenia: reduces positive and negative symptoms, improving overall functioning. - Psychotic disorders: alleviates acute psychotic episodes and stabilizes chronic psychosis. - Major depressive disorder (adjunct): enhances antidepressant response when added to standard therapy.

Amisulpride may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Akathisia: inner restlessness causing constant pacing or inability to stay still. - Nausea: mild to moderate stomach upset occurring after taking the medication. - Weight gain: gradual increase in body weight, often with increased appetite. - Hyperprolactinemia: elevated prolactin leading to menstrual changes, breast tenderness, or galactorrhea. - Somnolence: drowsiness or fatigue that may affect daily activities.

Serious or Rare Side Effects: - Tardive dyskinesia: persistent involuntary movements of face, tongue, or limbs, possibly irreversible. - Neuroleptic malignant syndrome: rare life‑threatening reaction with fever, rigidity, autonomic instability, altered mental status. - Severe hyperprolactinemia: markedly high prolactin causing galactorrhea, visual changes, or bone loss. - Agranulocytosis: drastic reduction in white blood cells, markedly increasing infection risk. - Cardiac QT prolongation: lengthening of QT interval on ECG, raising risk of serious arrhythmias.

When prescribing Amisulpride, clinicians should consider several precautionary measures to ensure safe use. - Dose adjustment: reduce dose in patients with renal impairment. - Monitoring: regularly assess prolactin levels and watch for endocrine disturbances. - Cardiovascular risk: evaluate baseline ECG for QT interval prolongation. - Elderly patients: use caution due to increased sensitivity to side effects. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Amisulpride can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - CYP450 inhibitors: co‑administration may increase plasma levels, raising toxicity risk. - QT‑prolonging drugs: combined use can exacerbate cardiac arrhythmia potential.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance orthostatic hypotension. - Dopamine agonists: can diminish antipsychotic effect. - Anticholinergic agents: may mask extrapyramidal symptoms. - CNS depressants: additive sedation may occur.